Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma
Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.
Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.
CAR T-cell therapies have been making their way through the field of multiple myeloma. Studies presented at the 2017 ASCO Annual Meeting showed that when targeting BCMA, CAR T-cell technology appeared to be tolerable and efficacious, Usmani says.
Larger cohorts are needed though, Usmani adds, as investigators still must indicate which patients will benefit from this therapy.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.
